KaloBios Pharmaceuticals

KaloBios to reduce workforce by 61%

Monday, November 9, 2015

KaloBios Pharmaceuticals, based in South San Francisco, Calif., will reduce its workforce as part of a plan to reduce operating costs. The action will reduce the company’s workforce by about 17 employees (or 61%), and will focus the company’s resources on the ongoing development of lenzilumab, also known as KB003, in chronic monomyelocytic leukemia (CMML), while it continues to pursue strategic alternatives for the company.

[Read More]

KaloBios publishes KB001 phase I study results

Monday, September 23, 2013

KaloBios Pharmaceuticals has published phase I study results for KB001, a first-generation, anti-Pseudomonas aeruginosa (Pa) type III secretion system (TTSS) antibody for use in patients with cystic fibrosis (CF). Data from this initial single-dose clinical study support the continuation of KaloBios’ ongoing phase II study of KB001-A, a second-generation, anti-TTSS antibody in CF patients with chronic Pa infections.

[Read More]

KaloBios initiates phase II study with KB001-A in cystic fibrosis

Friday, January 11, 2013

KaloBios Pharmaceuticals, a biopharmaceutical company based in San Francisco, Calif., has initiated dosing in a randomized, double-blind, placebo-controlled phase II clinical trial of KB001-A, the company’s anti-PcrV Humaneered, PEGylated monoclonal antibody fragment. The study will investigate the safety and efficacy of intravenously administered KB001-A as a treatment for chronic Pseudomonas aeruginosa (Pa) infection in cystic fibrosis patients.

[Read More]